Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). OncoTherapy Science's share price for the quarter that ended in Mar. 2026 was 円21. OncoTherapy Science's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 383.6 Mil. Therefore, OncoTherapy Science's market cap for the quarter that ended in Mar. 2026 was 円8,056.5 Mil.
OncoTherapy Science's quarterly market cap
increased
from Mar. 2025 (円7,606.0 Mil) to Sep. 2025 (円8,804.7 Mil) but then
declined
from Sep. 2025 (円8,804.7 Mil) to Mar. 2026 (円8,056.5 Mil).
OncoTherapy Science's annual market cap
increased
from Mar. 2024 (円4,570.5 Mil) to Mar. 2025 (円7,606.0 Mil) and
increased
from Mar. 2025 (円7,606.0 Mil) to Mar. 2026 (円8,056.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. OncoTherapy Science's Enterprise Value for Today is 円6,282.2 Mil.
OncoTherapy Science (TSE:4564) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
OncoTherapy Science Market Cap Related Terms
OncoTherapy Science Market Cap Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, OncoTherapy Science's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Market Cap distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
OncoTherapy Science's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (TSE:4564) has a Market Cap of 円8,371.5 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #901 out of 1421 companies in the Biotechnology industry, placing it in the top 63.4%.
Is OncoTherapy Science's Market Cap too high?
OncoTherapy Science's current Market Cap is 円8,371.5 Mil. Based on the distribution chart, OncoTherapy Science ranks #901 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #901 out of 1421 companies for Market Cap. This places OncoTherapy Science in the lower half of its industry. The industry median Market Cap is 121.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.57, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median Market Cap is 121.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current Market Cap is 円8,371.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.04, compared to a current price of 円21.00 — trading 23.2% above its estimated fair value. The current Market Cap is 円8,371.5 Mil. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Market Cap is 円8,371.5 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円21.00 is trading 23.2% above its estimated GF Value™ of 円17.04.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Market Cap: 円8,371.5 Mil
GF Value™: 円17.04 vs. price of 円21.00 (23.2% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
